Suppr超能文献

非酒精性脂肪性肝病患儿的无创参数和肝纤维化评分。

Noninvasive parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver disease.

机构信息

Department of Pediatrics, Seoul National University College of Medicine, Seoul, South Korea.

出版信息

World J Gastroenterol. 2012 Apr 7;18(13):1525-30. doi: 10.3748/wjg.v18.i13.1525.

Abstract

AIM

To evaluate the noninvasive parameters and hepatic fibrosis scores in obese children with nonalcoholic fatty liver disease (NAFLD).

METHODS

A total of 77 children diagnosed with NAFLD via liver biopsy were included and divided into 2 subgroups according to the histopathologic staging of hepatic fibrosis: mild (stage 0-1) vs significant fibrosis (stage 2-4). Clinical and laboratory parameters were evaluated in each patient. The aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ratio, AST/platelet ratio index (APRI), PGA index, Forns index, FIB-4, NAFLD fibrosis score, and pediatric NAFLD fibrosis index (PNFI) were calculated.

RESULTS

No clinical or biochemical parameter exhibited a significant difference between patients with mild and significant fibrosis. Among noninvasive hepatic fibrosis scores, only APRI and FIB4 revealed a significant difference between patients with mild and significant fibrosis (APRI: 0.67 ± 0.54 vs 0.78 ± 0.38, P = 0.032 and FIB4: 0.24 ± 0.12 vs 0.31 ± 0.21, P = 0.010). The area under the receiving operating characteristic curve of FIB4 was 0.81, followed by Forns index (0.73), APRI (0.70), NAFLD fibrosis score (0.58), AST/ALT ratio (0.53), PGA score (0.45), and PNFI (0.41).

CONCLUSION

APRI and FIB4 might be useful noninvasive hepatic fibrosis scores for predicting hepatic fibrosis in children with NAFLD.

摘要

目的

评估非酒精性脂肪性肝病(NAFLD)肥胖儿童的无创参数和肝纤维化评分。

方法

共纳入 77 例经肝活检诊断为 NAFLD 的患儿,根据肝纤维化的组织病理学分期分为轻度(0-1 期)和显著纤维化(2-4 期)两组。评估每位患者的临床和实验室参数。计算天门冬氨酸氨基转移酶(AST)/丙氨酸氨基转移酶(ALT)比值、AST/血小板比值指数(APRI)、PGA 指数、Forns 指数、FIB-4、NAFLD 纤维化评分和儿童 NAFLD 纤维化指数(PNFI)。

结果

轻度和显著纤维化患者的临床和生化参数无显著差异。在无创性肝纤维化评分中,仅 APRI 和 FIB4 在轻度和显著纤维化患者之间存在显著差异(APRI:0.67±0.54 与 0.78±0.38,P=0.032 和 FIB4:0.24±0.12 与 0.31±0.21,P=0.010)。FIB4 的受试者工作特征曲线下面积为 0.81,其次是 Forns 指数(0.73)、APRI(0.70)、NAFLD 纤维化评分(0.58)、AST/ALT 比值(0.53)、PGA 评分(0.45)和 PNFI(0.41)。

结论

APRI 和 FIB4 可能是预测儿童 NAFLD 肝纤维化的有用无创性肝纤维化评分。

相似文献

1
Noninvasive parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver disease.
World J Gastroenterol. 2012 Apr 7;18(13):1525-30. doi: 10.3748/wjg.v18.i13.1525.
2
Noninvasive scores are poorly predictive of histological fibrosis in paediatric fatty liver disease.
J Pediatr Gastroenterol Nutr. 2024 Jan;78(1):27-35. doi: 10.1002/jpn3.12068. Epub 2023 Dec 29.
3
The evaluation of hepatic fibrosis scores in children with nonalcoholic fatty liver disease.
Dig Dis Sci. 2015 May;60(5):1440-7. doi: 10.1007/s10620-014-3494-7. Epub 2014 Dec 25.
4
Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population.
BMC Gastroenterol. 2012 Jan 5;12:2. doi: 10.1186/1471-230X-12-2.
8
Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.
Dig Dis Sci. 2018 Sep;63(9):2259-2266. doi: 10.1007/s10620-018-5123-3. Epub 2018 May 19.
9
Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.
Clin Gastroenterol Hepatol. 2009 Oct;7(10):1104-12. doi: 10.1016/j.cgh.2009.05.033. Epub 2009 Jun 10.

引用本文的文献

2
KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease.
Clin Mol Hepatol. 2024 Sep;30(Suppl):S5-S105. doi: 10.3350/cmh.2024.0506. Epub 2024 Aug 19.
3
Serologic Biomarkers for Hepatic Fibrosis in Obese Children with Nonalcoholic Steatohepatitis.
Pediatr Gastroenterol Hepatol Nutr. 2024 Jul;27(4):236-245. doi: 10.5223/pghn.2024.27.4.236. Epub 2024 Jul 8.
4
TASL Practice Guidance on the Clinical Assessment and Management of Patients with Nonalcoholic Fatty Liver Disease.
Hepatol Forum. 2023 Mar 15;4(Suppl 1):1-32. doi: 10.14744/hf.2023.2023.0011. eCollection 2023.
5
Development of Fibro-PeN, a clinical prediction model for moderate-to-severe fibrosis in children with nonalcoholic fatty liver disease.
Hepatology. 2024 Jun 1;79(6):1381-1392. doi: 10.1097/HEP.0000000000000644. Epub 2023 Oct 23.
6
Noninvasive biomarkers in pediatric nonalcoholic fatty liver disease.
World J Hepatol. 2023 May 27;15(5):609-640. doi: 10.4254/wjh.v15.i5.609.
7
Fatty liver disease in children (MAFLD/PeFLD Type 2): unique classification considerations and challenges.
Ther Adv Endocrinol Metab. 2023 Mar 22;14:20420188231160388. doi: 10.1177/20420188231160388. eCollection 2023.
8
Nonalcoholic fatty liver disease and insulin resistance in children.
Clin Exp Pediatr. 2023 Dec;66(12):512-519. doi: 10.3345/cep.2022.01312. Epub 2023 Jan 9.
9
Liver fibrosis in children: a comprehensive review of mechanisms, diagnosis, and therapy.
Clin Exp Pediatr. 2023 Mar;66(3):110-124. doi: 10.3345/cep.2022.00367. Epub 2022 Dec 19.

本文引用的文献

1
Biomarkers of liver fibrosis.
J Gastroenterol Hepatol. 2011 May;26(5):802-9. doi: 10.1111/j.1440-1746.2010.06612.x.
2
A combination of the pediatric NAFLD fibrosis index and enhanced liver fibrosis test identifies children with fibrosis.
Clin Gastroenterol Hepatol. 2011 Feb;9(2):150-5. doi: 10.1016/j.cgh.2010.09.015. Epub 2010 Oct 1.
3
Hyaluronic acid predicts hepatic fibrosis in children with nonalcoholic fatty liver disease.
Transl Res. 2010 Oct;156(4):229-34. doi: 10.1016/j.trsl.2010.05.008. Epub 2010 Jun 22.
5
Pathology and biopsy assessment of non-alcoholic fatty liver disease.
Dig Dis. 2010;28(1):197-202. doi: 10.1159/000282086. Epub 2010 May 7.
7
Clinical and histological features of nonalcoholic fatty liver disease in children.
Dig Dis Sci. 2009 Oct;54(10):2225-30. doi: 10.1007/s10620-009-0949-3. Epub 2009 Aug 21.
8
Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study.
Hepatology. 2009 Oct;50(4):1113-20. doi: 10.1002/hep.23133.
9
Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease.
Clin Gastroenterol Hepatol. 2009 Oct;7(10):1104-12. doi: 10.1016/j.cgh.2009.05.033. Epub 2009 Jun 10.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验